Search results for "mutations"

showing 10 items of 205 documents

HETEROGENITY OF AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA IN SICILY

2004

AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIAMUTATIONSEPIDEMIOLOGY
researchProduct

CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia

2005

Contains fulltext : 47591.pdf (Publisher’s version ) (Closed access) Achromatopsia is a congenital, autosomal recessively inherited disorder characterized by a lack of color discrimination, low visual acuity (<0.2), photophobia, and nystagmus. Mutations in the genes for CNGA3, CNGB3, and GNAT2 have been associated with this disorder. Here, we analyzed the spectrum and prevalence of CNGB3 gene mutations in a cohort of 341 independent patients with achromatopsia. In 163 patients, CNGB3 mutations could be identified. A total of 105 achromats carried apparent homozygous mutations, 44 were compound (double) heterozygotes, and 14 patients had only a single mutant allele. The derived CNGB3 mutatio…

AchromatopsiaGenetics and epigenetic pathways of disease [NCMLS 6]genetic structuresGATED CATION CHANNELCNGB3 mutationsNonsense mutationMutantCyclic Nucleotide-Gated Cation ChannelsColor Vision DefectsGenes RecessiveLocus (genetics)Gene mutationBiologyTOTAL COLOURBLINDNESSIon ChannelsCLONINGDogscyclic nucleotide-gated channelGNAT2GeneticsmedicineLOCUSAnimalsHumansMissense mutationNeurosensory disorders [UMCN 3.3]ACHM3 locusDog DiseasesAlleleAllelesGenetics (clinical)Geneticstotal colorblindnessGNAT2PHOTORECEPTORSDYSTROPHYmedicine.diseaseCONE DEGENERATIONGENEeye diseasesPhenotypeEvaluation of complex medical interventions [NCEBP 2]MutationRetinal Cone Photoreceptor Cellssense organsachromatopsiarod monochromacyALPHA-SUBUNIThuman activities
researchProduct

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target

2018

Blastic Plasmacytoid Dendritic Cell Neoplasm is a rare and aggressive hematological malignancy currently lacking an effective therapy. To possibly identify genetic alterations useful for a new treatment design, we analyzed by whole-exome sequencing fourteen Blastic Plasmacytoid Dendritic Cell Neoplasm patients and the patient-derived CAL-1 cell line. The functional enrichment analysis of mutational data reported the epigenetic regulatory program as the most significantly undermined (P&lt;.0001). In particular, twenty-five epigenetic-modifiers were found mutated (e.g., ASXL1, TET2, SUZ12, ARID1A, PHF2, CHD8); ASXL1 was the most frequently affected (28.6% of cases). To evaluate the impact of …

Acute Myeloid LeukemiaBlastic plasmacytoid dendritic cell neoplasm epigenetic mutationsSkin NeoplasmsAzacitidineDecitabinePlasmacytoid dendritic cellGene mutationBiologyDecitabineBPDCNArticleEpigenesis Genetic03 medical and health sciences0302 clinical medicineHistone methylation5’-Azacytidine; Acute Myeloid Leukemia; BPDCN; Decitabine; WESmedicineHumansEpigeneticsExome sequencingRegulation of gene expressionMyeloproliferative DisordersDendritic CellsGenomicsHematology5 -AzacytidineMyeloid Neoplasms5’-AzacytidineCancer researchWES030215 immunologymedicine.drugHaematologica
researchProduct

Gastric adenomas: relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression.

2006

Gastric adenomas are rare neoplastic growths characterized by localized polypoid proliferations of dysplastic epithelium that tend to progress to infiltrating adenocarcinoma. Therefore, the identification of molecular markers that could reliably recognize adenomas at risk of progression is advocated in the clinical management. In this study we investigated, in a series of gastric adenoma specimens from an area at high risk of gastric cancer, the relationship between clinicopathological characteristics of adenoma and Helicobacter pylori infection, APC mutational status, and COX-2 and the down-stream enzyme mPGES1 expression. Helicobacter pylori infection, detected in 24%, and 33% by histolog…

AdenomaMaleGenes APCAdenomaAdenocarcinomamedicine.disease_causegastric adenomaHelicobacter InfectionsHelicobacter pyloryStomach NeoplasmsmedicineHumansAPC mutationsAgedProstaglandin-E SynthasesAged 80 and overMutationbiologyHelicobacter pyloribusiness.industryCancerAPC mutations; COX-2; gastric adenoma; Helicobacter pyloriHistologyHematologyHelicobacter pyloriCOX-2Middle Agedmedicine.diseasebiology.organism_classificationdigestive system diseasesEpitheliumIntramolecular Oxidoreductasesmedicine.anatomical_structureOncologyDysplasiacyclooxygenase-2Cyclooxygenase 2Gastric MucosaMutationCancer researchAPC-mutations gastric adenoma Helycobacter pyloriAdenocarcinomaFemalebusiness
researchProduct

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

2011

Abstract The purpose of this work was to determine whether there are differences in PIK3CA mutation status and PTEN protein expression between primary and matched metastatic breast tumors as this could influence patient management. Paraffin sections of 50 μm were used for DNA extraction and slides of 3 μm for immunohistochemistry (IHC) and FISH. Estrogen receptor, progesterone receptor, and HER2 IHC were repeated in a central laboratory for both primary tumors and metastases. PTEN levels were assessed by IHC and phosphoinositide 3-kinase (PI3K) pathway mutations were detected by a mass spectroscopy–based approach. Median age was 48 years (range: 30–83 years). Tumor subtype included 72% horm…

AdultCancer Researchmedicine.medical_specialtyClass I Phosphatidylinositol 3-KinasesReceptor ErbB-2Breast Neoplasmsmedicine.disease_causeArticleMetastasisMetastasisPhosphatidylinositol 3-KinasesBreast cancerInternal medicineBreast CancermedicinePTENHumansPTEN lossReceptorneoplasmsPI3K/AKT/mTOR pathwayAgedAged 80 and overMutationbiologyPTEN PhosphohydrolaseMiddle Agedmedicine.diseaseMetastatic breast cancerEndocrinologyOncologyReceptors EstrogenMutationbiology.proteinCancer researchImmunohistochemistryFemalePIK3CA mutationsReceptors ProgesteroneSignal TransductionMolecular cancer therapeutics
researchProduct

MicroRNAs expression associated with aggressive clinicopathological features and poor prognosis in primary cutaneous melanomas

2020

Several studies have focused on identifying microRNAs involved in the pathogenesis of melanoma. However, its association with clinicopathological features has been scarcely addressed. The aim of this study is to identify microRNAs expression profiles related to aggressive clinicopathological and molecular features, and to analyze the association with melanoma survival. A retrospective and observational study was performed in a series of 179 formalin-fixed paraffin embedded primary cutaneous melanomas. First, a screening analysis on a discovery set (n = 22) using miRNA gene chip array (Affymetrix, Santa Clara, California, USA) was performed. Differentially expressed microRNAs were detected e…

AdultMale0301 basic medicineCancer ResearchPoor prognosisSkin NeoplasmsTERT mutationsDermatologyBiologyPathogenesisBreslow Thickness03 medical and health sciences0302 clinical medicinemicroRNAmelanomamedicineHumansMelanomaMitosisSurvival analysisAgedMelanomaMicroRNA Expression ProfileMiddle AgedPrognosismedicine.diseasemicroRNAsMicroRNAs030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchFemaleprognosisclinicopathological featuresMelanoma Research
researchProduct

Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology

2016

Somatic mutation analysis represents a useful tool in selecting personalized therapy. The aim of our study was to determine the presence of common genetic events affecting actionable oncogenes using a MassARRAY technology in patients with advanced solid tumors who were potential candidates for target-based therapies. The analysis of 238 mutations across 19 oncogenes was performed in 197 formalin-fixed paraffin-embedded samples of different tumors using the OncoCarta Panel v1.0 (Sequenom Hamburg, Germany). Of the 197 specimens, 97 (49.2%) presented at least one mutation. Forty-nine different oncogenic mutations in 16 genes were detected. Mutations in KRAS and PIK3CA were detected in 40/97 (4…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyColorectal cancersomatic oncogene mutationsDNA Mutational Analysismedicine.disease_cause03 medical and health sciences0302 clinical medicineGermline mutationNeoplasmsInternal medicineHumansMedicineoncocartaPrecision MedicineGeneAgedAged 80 and overGeneticsMutationbusiness.industryHigh-Throughput Nucleotide Sequencingpersonalized medicineMiddle AgedPrecision medicinemedicine.diseaseClinical trial030104 developmental biologyOncologySpectrometry Mass Matrix-Assisted Laser Desorption-Ionization030220 oncology & carcinogenesisFemalePersonalized medicineKRASbusinessResearch PaperOncotarget
researchProduct

Molecular characterization of congenital myasthenic syndromes in Spain.

2017

Congenital myasthenic syndromes (CMS) are a heterogeneous group of genetic disorders, all of which impair neuromuscular transmission. Epidemiological data and frequencies of gene mutations are scarce in the literature. Here we describe the molecular genetic and clinical findings of sixty-four genetically confirmed CMS patients from Spain. Thirty-six mutations in the CHRNE, RAPSN, COLQ, GFPT1, DOK7, CHRNG, GMPPB, CHAT, CHRNA1, and CHRNB1 genes were identified in our patients, with five of them not reported so far.. These data provide an overview on the relative frequencies of the different CMS subtypes in a large Spanish population. CHRNE mutations are the most common cause of CMS in Spain, …

AdultMale0301 basic medicineSlow-channel syndromeAdolescentNeuromuscular transmissionGMPPBGene mutationCOLQCongenital myasthenic syndromeYoung Adult03 medical and health sciences0302 clinical medicineDOK7COLQmedicineHumansCHRNECHRNEGeneGenetics (clinical)health care economics and organizationsMyasthenic Syndromes CongenitalGeneticsbiologyRAPSNMiddle AgedCongenital myasthenic syndromemedicine.diseasePhenotype3. Good healthGenetic mutationsRAPSN030104 developmental biologyGFPT1NeurologySpainPediatrics Perinatology and Child Healthbiology.proteinFemaleNeurology (clinical)030217 neurology & neurosurgery
researchProduct

Mutation spectrum and clinical investigation of achromatopsia patients with mutations in the GNAT2 gene

2019

Achromatopsia (ACHM) is a hereditary cone photoreceptor disorder characterized by the inability to discriminate colors, nystagmus, photophobia, and low-visual acuity. Six genes have been associated with this rare autosomal recessively inherited disease, including the GNAT2 gene encoding the catalytic α-subunit of the G-protein transducin which is expressed in the cone photoreceptor outer segment. Out of a cohort of 1,116 independent families diagnosed with a primary clinical diagnosis of ACHM, we identified 23 patients with ACHM from 19 independent families with likely causative mutations in GNAT2, representing 1.7% of our large ACHM cohort. In total 22 different potentially disease-causing…

AdultMaleAchromatopsiagenetic structuresAdolescentChild preschoolDNA Copy Number VariationsColor Vision DefectsBiologymedicine.disease_causeHeterotrimeric GTP-Binding Proteins/genetics03 medical and health sciencesExonGene duplicationGeneticsmedicineHumansGenetic Predisposition to DiseaseCopy-number variationColor Vision Defects/geneticsChildGenetics (clinical)030304 developmental biologyAgedGenetics0303 health sciencesGNAT2MutationSettore MED/30 - Malattie Apparato Visivo030305 genetics & heredityBreakpointInfantSequence Analysis DNAExonsMiddle Agedmedicine.diseaseHeterotrimeric GTP-Binding ProteinsPhotoreceptor outer segmenteye diseasesPedigreeSettore BIO/18 - GeneticaSequence Analysis DNA/methodsyoung adultFemalesense organsachromatopsia copy number variations GNAT2 mutations transducinmutation
researchProduct

FUS mutations in sporadic amyotrophic lateral sclerosis

2011

Mutations in the FUS gene have recently been described as a cause of familial amyotrophic lateral sclerosis (ALS), but their role in the pathogenesis of sporadic ALS is unclear. We undertook mutational screening of all coding exons of FUS in 228 sporadic ALS cases, and, as previous reports suggest that exon 15 represents a mutational hotspot, we sequenced this exon in an additional 1295 sporadic cases. Six variants in six different cases were found, indicating that FUS mutations can underlie apparently sporadic ALS, but account for less than 1% of this form of disease. © 2010 .

AdultMaleAgingAmyotrophic lateral sclerosis; FUS; Italy; Sporadic disease; United States of America;AdolescentGenotypesporadic patientsDNA Mutational AnalysisALS; FUS mutations; sporadic patientsBiologymedicine.disease_causeArticlePathogenesisExonYoung AdultDNA Mutational AnalysisGenotypemedicineHumansFUS mutationsAmyotrophic lateral sclerosisChildGeneAgedGeneticsAged 80 and overMutationGeneral NeuroscienceAmyotrophic Lateral Sclerosisamyotrophic lateral sclerosis FUS geneticsExonsMiddle Agedmedicine.diseaseUnited StatesSettore MED/26 - NEUROLOGIAItalyMutationRNA-Binding Protein FUSFemaleNeurology (clinical)Geriatrics and GerontologyALSDevelopmental BiologyRNA-Binding Protein FUS
researchProduct